Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.

Yano H, Andrews LP, Workman CJ, Vignali DAA.

Immunology. 2019 Jul;157(3):232-247. doi: 10.1111/imm.13067. Epub 2019 Jun 3. Review.

PMID:
31087644
2.

A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies.

Sun Z, Chen L, Xin H, Jiang Y, Huang Q, Cillo AR, Tabib T, Kolls JK, Bruno TC, Lafyatis R, Vignali DAA, Chen K, Ding Y, Hu M, Chen W.

Nat Commun. 2019 Apr 9;10(1):1649. doi: 10.1038/s41467-019-09639-3.

3.

Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion.

Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA.

Nat Immunol. 2019 Jun;20(6):724-735. doi: 10.1038/s41590-019-0346-9. Epub 2019 Apr 1.

PMID:
30936494
4.

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L.

Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20.

PMID:
30580966
5.

Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Overacre-Delgoffe AE, Vignali DAA.

Cancer Immunol Res. 2018 Aug;6(8):882-887. doi: 10.1158/2326-6066.CIR-18-0066. Review.

PMID:
30068755
6.

B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex.

Podojil JR, Chiang MY, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, Chen L, Vignali DAA, Miller SD.

J Immunol. 2018 Aug 1;201(3):897-907. doi: 10.4049/jimmunol.1700811. Epub 2018 Jun 13.

PMID:
29898965
7.

Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism.

Du T, Zhu L, Levine KM, Tasdemir N, Lee AV, Vignali DAA, Houten BV, Tseng GC, Oesterreich S.

Sci Rep. 2018 May 8;8(1):7205. doi: 10.1038/s41598-018-25357-0.

8.

Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.

Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA.

J Natl Cancer Inst. 2018 Jul 1;110(7):696-698. doi: 10.1093/jnci/djy014. No abstract available.

PMID:
29471462
9.

Treg-specific IL-27Rα deletion uncovers a key role for IL-27 in Treg function to control autoimmunity.

Do J, Kim D, Kim S, Valentin-Torres A, Dvorina N, Jang E, Nagarajavel V, DeSilva TM, Li X, Ting AH, Vignali DAA, Stohlman SA, Baldwin WM 3rd, Min B.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10190-10195. doi: 10.1073/pnas.1703100114. Epub 2017 Sep 5.

10.

LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.

Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, Normolle D, Bettini M, Workman CJ, Vignali DAA.

Sci Immunol. 2017 Mar 31;2(9). pii: eaah4569. doi: 10.1126/sciimmunol.aah4569.

11.

Cutting Edge: CD3 ITAM Diversity Is Required for Optimal TCR Signaling and Thymocyte Development.

Bettini ML, Chou PC, Guy CS, Lee T, Vignali KM, Vignali DAA.

J Immunol. 2017 Sep 1;199(5):1555-1560. doi: 10.4049/jimmunol.1700069. Epub 2017 Jul 21.

12.

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, Vignali DAA.

Cell. 2017 Jun 1;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. Epub 2017 May 25.

13.

Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Ratay ML, Glowacki AJ, Balmert SC, Acharya AP, Polat J, Andrews LP, Fedorchak MV, Schuman JS, Vignali DAA, Little SR.

J Control Release. 2017 Jul 28;258:208-217. doi: 10.1016/j.jconrel.2017.05.007. Epub 2017 May 10.

PMID:
28501670
14.

Globule Leukocytes and Other Mast Cells in the Mouse Intestine.

Vogel P, Janke L, Gravano DM, Lu M, Sawant DV, Bush D, Shuyu E, Vignali DAA, Pillai A, Rehg JE.

Vet Pathol. 2018 Jan;55(1):76-97. doi: 10.1177/0300985817705174. Epub 2017 May 11.

PMID:
28494703
15.

LAG3 (CD223) as a cancer immunotherapy target.

Andrews LP, Marciscano AE, Drake CG, Vignali DA.

Immunol Rev. 2017 Mar;276(1):80-96. doi: 10.1111/imr.12519. Review.

16.

Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Visperas A, Vignali DA.

J Immunol. 2016 Nov 15;197(10):3762-3770. Review.

17.

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM.

Science. 2016 Sep 30;353(6307). pii: aah3374.

18.

Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade.

Tomita Y, Satomi M, Bracamonte-Baran W, Jankowska Gan E, Workman AS, Workman CJ, Vignali DA, Burlingham WJ.

Transplant Direct. 2016 Apr 21;2(5):e73. doi: 10.1097/TXD.0000000000000580. eCollection 2016 May.

19.

Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling.

Dobbins J, Gagnon E, Godec J, Pyrdol J, Vignali DA, Sharpe AH, Wucherpfennig KW.

Sci Signal. 2016 Jul 26;9(438):ra75. doi: 10.1126/scisignal.aaf0626.

20.

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Zhang Q, Vignali DA.

Immunity. 2016 May 17;44(5):1034-51. doi: 10.1016/j.immuni.2016.04.017. Review.

21.

Interleukin-35 Limits Anti-Tumor Immunity.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA.

Immunity. 2016 Feb 16;44(2):316-29. doi: 10.1016/j.immuni.2016.01.013. Epub 2016 Feb 9.

22.

Targeting regulatory T cells in tumors.

Liu C, Workman CJ, Vignali DA.

FEBS J. 2016 Jul;283(14):2731-48. doi: 10.1111/febs.13656. Epub 2016 Mar 1. Review.

23.

T(reg) stability: to be or not to be.

Overacre AE, Vignali DA.

Curr Opin Immunol. 2016 Apr;39:39-43. doi: 10.1016/j.coi.2015.12.009. Epub 2016 Jan 15. Review.

24.

Mucosal Administration of Collagen V Ameliorates the Atherosclerotic Plaque Burden by Inducing Interleukin 35-dependent Tolerance.

Park AC, Huang G, Jankowska-Gan E, Massoudi D, Kernien JF, Vignali DA, Sullivan JA, Wilkes DS, Burlingham WJ, Greenspan DS.

J Biol Chem. 2016 Feb 12;291(7):3359-70. doi: 10.1074/jbc.M115.681882. Epub 2015 Dec 31.

25.

Identification of the Docking Site for CD3 on the T Cell Receptor β Chain by Solution NMR.

He Y, Rangarajan S, Kerzic M, Luo M, Chen Y, Wang Q, Yin Y, Workman CJ, Vignali KM, Vignali DA, Mariuzza RA, Orban J.

J Biol Chem. 2015 Aug 7;290(32):19796-805. doi: 10.1074/jbc.M115.663799. Epub 2015 Jun 24.

26.

Inhibitory receptors as targets for cancer immunotherapy.

Turnis ME, Andrews LP, Vignali DA.

Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413. Review.

27.

An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy.

Do JS, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, Jang E, Stohlman SA, Shen B, Fairchild RL, Baldwin WM III, Vignali DA, Min B.

Mucosal Immunol. 2016 Jan;9(1):137-45. doi: 10.1038/mi.2015.45. Epub 2015 May 27.

28.

Interleukin-35: Expanding Its Job Profile.

Sawant DV, Hamilton K, Vignali DA.

J Interferon Cytokine Res. 2015 Jul;35(7):499-512. doi: 10.1089/jir.2015.0015. Epub 2015 Apr 28. Review.

29.

Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members.

Dixon KO, van der Kooij SW, Vignali DA, van Kooten C.

Eur J Immunol. 2015 Jun;45(6):1736-47. doi: 10.1002/eji.201445217.

30.

Inducible T-cell receptor expression in precursor T cells for leukemia control.

Hoseini SS, Hapke M, Herbst J, Wedekind D, Baumann R, Heinz N, Schiedlmeier B, Vignali DA, van den Brink MR, Schambach A, Blazar BR, Sauer MG.

Leukemia. 2015 Jul;29(7):1530-42. doi: 10.1038/leu.2015.20. Epub 2015 Feb 5.

31.

TIM-1 signaling is required for maintenance and induction of regulatory B cells.

Yeung MY, Ding Q, Brooks CR, Xiao S, Workman CJ, Vignali DA, Ueno T, Padera RF, Kuchroo VK, Najafian N, Rothstein DM.

Am J Transplant. 2015 Apr;15(4):942-53. doi: 10.1111/ajt.13087. Epub 2015 Feb 2.

32.

IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects.

Liu Y, Wu Y, Wang Y, Cai Y, Hu B, Bao G, Fang H, Zhao L, Ma S, Cheng Q, Song Y, Liu Y, Zhu Z, Chang H, Yu X, Sun A, Zhang Y, Vignali DA, Wu D, Liu H.

Leukemia. 2015 Apr;29(4):939-46. doi: 10.1038/leu.2014.310. Epub 2014 Nov 3.

33.

Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease.

Ito Y, Hashimoto M, Hirota K, Ohkura N, Morikawa H, Nishikawa H, Tanaka A, Furu M, Ito H, Fujii T, Nomura T, Yamazaki S, Morita A, Vignali DA, Kappler JW, Matsuda S, Mimori T, Sakaguchi N, Sakaguchi S.

Science. 2014 Oct 17;346(6207):363-8. doi: 10.1126/science.1259077.

34.

Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity.

Jha V, Workman CJ, McGaha TL, Li L, Vas J, Vignali DA, Monestier M.

PLoS One. 2014 Aug 14;9(8):e104484. doi: 10.1371/journal.pone.0104484. eCollection 2014.

35.

TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential.

Bettini M, Blanchfield L, Castellaw A, Zhang Q, Nakayama M, Smeltzer MP, Zhang H, Hogquist KA, Evavold BD, Vignali DA.

J Immunol. 2014 Jul 15;193(2):571-9. doi: 10.4049/jimmunol.1400043. Epub 2014 Jun 18.

36.

Membrane association of the CD3ε signaling domain is required for optimal T cell development and function.

Bettini ML, Guy C, Dash P, Vignali KM, Hamm DE, Dobbins J, Gagnon E, Thomas PG, Wucherpfennig KW, Vignali DA.

J Immunol. 2014 Jul 1;193(1):258-67. doi: 10.4049/jimmunol.1400322. Epub 2014 Jun 4.

37.

Once a Treg, always a Treg?

Sawant DV, Vignali DA.

Immunol Rev. 2014 May;259(1):173-91. doi: 10.1111/imr.12173. Review.

38.

A Fox of a different color: FoxA1 programs a new regulatory T cell subset.

Delgoffe GM, Vignali DA.

Nat Med. 2014 Mar;20(3):236-7. doi: 10.1038/nm.3493. No abstract available.

PMID:
24603791
39.

Regulatory T cells limit induction of protective immunity and promote immune pathology following intestinal helminth infection.

Sawant DV, Gravano DM, Vogel P, Giacomin P, Artis D, Vignali DA.

J Immunol. 2014 Mar 15;192(6):2904-12. doi: 10.4049/jimmunol.1202502. Epub 2014 Feb 14.

40.

Interview: immunotherapeutic manipulation of the tumor microenvironment.

Vignali DA.

Immunotherapy. 2013 Dec;5(12):1279-81. doi: 10.2217/imt.13.135. No abstract available.

41.

STAT heterodimers in immunity: A mixed message or a unique signal?

Delgoffe GM, Vignali DA.

JAKSTAT. 2013 Jan 1;2(1):e23060. doi: 10.4161/jkst.23060. Review.

42.

Generation of T cell receptor-retrogenic mice: improved retroviral-mediated stem cell gene transfer.

Bettini ML, Bettini M, Nakayama M, Guy CS, Vignali DA.

Nat Protoc. 2013 Oct;8(10):1837-40. doi: 10.1038/nprot.2013.111. Epub 2013 Sep 5.

43.

Inhibitory role of the transcription repressor Gfi1 in the generation of thymus-derived regulatory T cells.

Shi LZ, Kalupahana NS, Turnis ME, Neale G, Hock H, Vignali DA, Chi H.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3198-205. doi: 10.1073/pnas.1300950110. Epub 2013 Aug 5.

44.

Retraction. Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance.

Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA.

J Immunol. 2013 Aug 15;191(4):2018. doi: 10.4049/jimmunol.1390040. No abstract available.

45.

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis.

Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, Vignali DA.

Nature. 2013 Sep 12;501(7466):252-6. doi: 10.1038/nature12428. Epub 2013 Aug 4.

46.

The plasticity and stability of regulatory T cells.

Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H.

Nat Rev Immunol. 2013 Jun;13(6):461-7. doi: 10.1038/nri3464. Epub 2013 May 17.

PMID:
23681097
47.

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Herold KC, Vignali DA, Cooke A, Bluestone JA.

Nat Rev Immunol. 2013 Apr;13(4):243-56. doi: 10.1038/nri3422. Review.

48.

Regulatory T cells: recommendations to simplify the nomenclature.

Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF.

Nat Immunol. 2013 Apr;14(4):307-8. doi: 10.1038/ni.2554. No abstract available.

49.

Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.

Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA.

Nat Immunol. 2013 Mar;14(3):262-70. doi: 10.1038/ni.2538. Epub 2013 Feb 3.

50.

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.

Turnis ME, Korman AJ, Drake CG, Vignali DA.

Oncoimmunology. 2012 Oct 1;1(7):1172-1174.

Supplemental Content

Loading ...
Support Center